Belgian Drug Developer Agomab Therapeutics Files for United States Initial Public Offering
Agomab Therapeutics filed for a U.S. IPO on January 16, 2026. The Belgian biotech firm aims to list on the Nasdaq during a recovery for clinical drug developers.
Insights:
Agomab Therapeutics filed for an initial public offering in the United States 
USon January 16, 2026. The pre-revenue drug developer based in Antwerp, Belgium 
BE, plans to list its shares on the Nasdaq Global Market under the ticker symbol AGMB. This move highlights a strengthening IPO market for clinical-stage biotechnology companies, supported by broader investor interest and expectations of upcoming interest rate cuts throughout 2026. Agomabcurrently has no approved products and generates no revenue.
USon January 16, 2026. The pre-revenue drug developer based in Antwerp, Belgium BE, plans to list its shares on the Nasdaq Global Market under the ticker symbol AGMB. This move highlights a strengthening IPO market for clinical-stage biotechnology companies, supported by broader investor interest and expectations of upcoming interest rate cuts throughout 2026. Agomabcurrently has no approved products and generates no revenue.The company reported a widening net loss of €45.1 million for the nine-month period ending September 30, 2025, compared to a loss of €34.5 million during the same period in 2024. This financial trajectory follows a significant increase in research and development spending, which rose to €35 million in the latest nine-month period from €28.6 million a year earlier. Since its founding in 2017, Agomab Therapeuticshas raised approximately €300 million from various venture capital and institutional firms.
